Potential Clinical Uses of CDK Inhibitors: Lessons from Synthetic Lethality Screens

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15310%2F15%3A33157602" target="_blank" >RIV/61989592:15310/15:33157602 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/61389030:_____/15:00450910

Výsledek na webu

<a href="http://onlinelibrary.wiley.com/doi/10.1002/med.21354/epdf" target="_blank" >http://onlinelibrary.wiley.com/doi/10.1002/med.21354/epdf</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1002/med.21354" target="_blank" >10.1002/med.21354</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Potential Clinical Uses of CDK Inhibitors: Lessons from Synthetic Lethality Screens

Popis výsledku v původním jazyce

Developments in genetic and genomic technology have produced vast quantities of data that are gradually yielding new insights into fundamental cellular and molecular processes. In particular, they have revealed some differences between normal and transformed cells that could potentially be exploited to develop targeted, personalized cancer therapies with unprecedented efficiencies. This review summarizes recent findings from synthetic lethality (SL) screens against cyclin-dependent kinases (CDKs) that can be targeted with small molecule kinase inhibitors. SL screens can be used to identify cancers sensitive to CDK inhibitors. Several SL partners of specific CDKs have been identified, including MYC, K-Ras, VHL, PI3K, and PARP, all of which are discussedin the review. CDK inhibitors have been in clinical trials for nearly 20 years and it has become clear that effective therapy using these compounds will require careful selection of patients with respect to the specific molecular phenoty

Název v anglickém jazyce

Potential Clinical Uses of CDK Inhibitors: Lessons from Synthetic Lethality Screens

Popis výsledku anglicky

Developments in genetic and genomic technology have produced vast quantities of data that are gradually yielding new insights into fundamental cellular and molecular processes. In particular, they have revealed some differences between normal and transformed cells that could potentially be exploited to develop targeted, personalized cancer therapies with unprecedented efficiencies. This review summarizes recent findings from synthetic lethality (SL) screens against cyclin-dependent kinases (CDKs) that can be targeted with small molecule kinase inhibitors. SL screens can be used to identify cancers sensitive to CDK inhibitors. Several SL partners of specific CDKs have been identified, including MYC, K-Ras, VHL, PI3K, and PARP, all of which are discussedin the review. CDK inhibitors have been in clinical trials for nearly 20 years and it has become clear that effective therapy using these compounds will require careful selection of patients with respect to the specific molecular phenoty

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

CE - Biochemie

OECD FORD obor

—

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Medicinal Research Reviews

ISSN

0198-6325

e-ISSN

—

Svazek periodika

35

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

19

Strana od-do

1156-1174

Kód UT WoS článku

000362795200003

EID výsledku v databázi Scopus

—